Adherence and resource use among psoriasis patients treated with biologics

References

• Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386(9997):983–994.
   PubMed Web of Science ®Google Scholar
• Iskandar IYK, Ashcroft DM, Warren RB, et al. Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis. Br J Dermatol. 2017;177(5):1410–1421.
   PubMed Web of Science ®Google Scholar
• Schaefer CP, Cappelleri JC, Cheng R, et al. Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States. J Am Acad Dermatol. 2015;73(4):585–93.e3.
   PubMed Web of Science ®Google Scholar
• World Health Organization – Adherence to long-term therapies: evidence for action. World Health Organization WHO [Internet]. 2015 [cited 2017 Oct 23]. Available from: http://www.who.int/chp/knowledge/publications/adherence_report/en/
   Google Scholar
• Thorneloe RJ, Bundy C, Griffiths CE, et al. Adherence to medication in patients with psoriasis: a systematic literature review. Br J Dermatol. 2013;168(1):20–31.
   PubMed Web of Science ®Google Scholar
• Zschocke I, Ortland C, Reich K. Evaluation of adherence predictors for the treatment of moderate to severe psoriasis with biologics: the importance of physician-patient interaction and communication. J Eur Acad Dermatol Venereol. 2017;31(6):1014–1020.
   PubMed Web of Science ®Google Scholar
• Hambly R, Kelly A, Gilhooley E, et al. Medication adherence among patients with psoriasis on traditional systemic and biologics treatment. Br J Dermatol. 2018;178(1):e46–e8.
   PubMed Web of Science ®Google Scholar
• Ross C, Marshman G, Grillo M, et al. Biological therapies for psoriasis: adherence and outcome analysis from a clinical perspective. Australas J Dermatol. 2016;57(2):137–140.
   PubMed Web of Science ®Google Scholar
• Sandoval LF, Huang KE, Feldman SR. Adherence to ustekinumab in psoriasis patients. JDD. 2013;12(10):1090–1092.
   PubMed Web of Science ®Google Scholar
• Fenerty SD, West C, Davis SA, et al. The effect of reminder systems on patients’ adherence to treatment. Patient Prefer Adherence. 2012;6:127–135.
   PubMed Web of Science ®Google Scholar
• West C, Narahari S, O’Neill J, et al. Adherence to adalimumab in patients with moderate to severe psoriasis. Dermatol Online J. 2013;19(5):18182.
   PubMedGoogle Scholar
• Hsu DY, Gniadecki R. Patient adherence to biologic agents in psoriasis. Dermatology. 2016;232(3):326–333.
   PubMed Web of Science ®Google Scholar
• Kabore L, Muntner P, Chamot E, et al. Self-report measures in the assessment of antiretroviral medication adherence: comparison with medication possession ratio and HIV viral load. J Int Assoc Provid AIDS Care. 2015;14(2):156–162.
   PubMedGoogle Scholar
• Levin AA, Gottlieb AB, Au SC. A comparison of psoriasis drug failure rates and reasons for discontinuation in biologics vs conventional systemic therapies. JDD. 2014;13(7):848–853.
   PubMed Web of Science ®Google Scholar
• Doshi JA, Takeshita J, Pinto L, et al. Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population. J Am Acad Dermatol. 2016;74(6):1057–65.e4.
   PubMed Web of Science ®Google Scholar
• Takeshita J, Gelfand JM, Li P, et al. Psoriasis in the US medicare population: prevalence, treatment, and factors associated with biologic use. J Invest Dermatol. 2015;135(12):2955–2963.
   PubMed Web of Science ®Google Scholar
• Lewis DJ, Cardwell LA, Feldman SR. Applying behavioural economics to psoriasis treatment: interventions to improve patient adherence to biologics. J Eur Acad Dermatol Venereol. 2018;32(2):e65–e6.
   PubMed Web of Science ®Google Scholar
• Oussedik E, Cardwell LA, Patel NU, et al. An anchoring-based intervention to increase patient willingness to use injectable medication in psoriasis. JAMA Dermatol. 2017;153(9):932–934.
   PubMed Web of Science ®Google Scholar
• Zhang M, Brenneman SK, Carter CT, et al. Patient-reported treatment satisfaction and choice of dosing frequency with biologic treatment for moderate to severe plaque psoriasis. Patient Prefer Adherence. 2015;9:777–784.
   PubMed Web of Science ®Google Scholar
• Honda H, Umezawa Y, Kikuchi S, et al. Switching of biologics in psoriasis: reasons and results. J Dermatol. 2017;44(9):1015–1019.
   PubMed Web of Science ®Google Scholar
• Belinchon I, Rivera R, Blanch C, et al. Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature. Patient Prefer Adherence. 2016;10:2357–2367.
   PubMed Web of Science ®Google Scholar
• Schaarschmidt ML, Kromer C, Herr R, et al. Treatment satisfaction of patients with psoriasis. Acta Derm Venereol. 2015;95(5):572–578.
   PubMed Web of Science ®Google Scholar
• Ragnarson TG, Hjortsberg C, Bjarnason A, et al. Treatment patterns, treatment satisfaction, severity of disease problems, and quality of life in patients with psoriasis in three Nordic countries. Acta Derm Venereol. 2013;93(4):442–445.
   PubMed Web of Science ®Google Scholar
• van den Reek JM, van Luumig PP, Otero ME, et al. Satisfaction of treatment with biologics is high in psoriasis: results from the Bio-CAPTURE network. Br J Dermatol. 2014;170(5):1158–1165.
   PubMed Web of Science ®Google Scholar
• Kromer C, Schaarschmidt ML, Schmieder A, et al. Patient preferences for treatment of psoriasis with biologicals: a discrete choice experiment. PloS One. 2015;10(6):e0129120.
   PubMed Web of Science ®Google Scholar
• Yu AP, Tang J, Xie J, et al. Economic burden of psoriasis compared to the general population and stratified by disease severity. Curr Med Res Opin. 2009;25(10):2429–2438.
   PubMed Web of Science ®Google Scholar
• Greenberg JD, Palmer JB, Li Y, et al. Healthcare resource use and direct costs in patients with ankylosing spondylitis and psoriatic arthritis in a large US cohort. J Rheumatol. 2016;43(1):88–96.
   PubMed Web of Science ®Google Scholar
• Sorensen EP, Algzlan H, Au SC, et al. Lower socioeconomic status is associated with decreased therapeutic response to the biologic agents in psoriasis patients. JDD. 2016;15(2):147–153.
   PubMed Web of Science ®Google Scholar
• Fonia A, Jackson K, Lereun C, et al. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis. Br J Dermatol. 2010;163(4):807–816.
   PubMed Web of Science ®Google Scholar
• Foster SA, Zhu B, Guo J, et al. Patient characteristics, health care resource utilization, and costs associated with treatment-regimen failure with biologics in the treatment of psoriasis. J Manag Care Spec Pharm. 2016;22(4):396–405.
   PubMedGoogle Scholar
• Abdelnabi M, Patel A, Rengifo-Pardo M, et al. Insurance coverage of biologics for moderate-to-severe psoriasis: a retrospective, observational 5-year chart review. Am J Clin Dermatol. 2016;17(4):421–424.
   PubMed Web of Science ®Google Scholar
• Yentzer BA, Yelverton CB, Simpson GL, et al. Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis. Dermatol Online J. 2009;15(4):1.
   PubMedGoogle Scholar
• Cheng J, Feldman SR. The cost of biologics for psoriasis is increasing. Drugs Context. 2014;3:212266.
   PubMedGoogle Scholar
• Cohen AD, Wu JJ, Puig L, et al. Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. Br J Dermatol. 2017;177(6):1495–1502.
   PubMed Web of Science ®Google Scholar
• Blackstone EA, Fuhr JP Jr. Innovation and competition: will biosimilars succeed? The creation of an FDA approval pathway for biosimilars is complex and fraught with hazard. Yes, innovation and market competition are at stake. But so are efficacy and patient safety. Biotechnol Healthc. 2012;9(1):24–27.
   PubMedGoogle Scholar
• Feldman SR, Bagel J, Namak S. Biosimilars for immune-mediated chronic diseases in primary care: what a practicing physician needs to know. Am J Med Sci. 2018 May;355(5):411–417. Epub 2017 Dec 29; Review. PubMed PMID: 29753369.
   PubMed Web of Science ®Google Scholar
• Patel PK, King CR, Feldman SR. Biologics and biosimilars. J Dermatol Treat. 2015;26(4):299–302. Epub 2015 Jun 24. PubMedPMID: 26105205.
   PubMed Web of Science ®Google Scholar